Endometrial Cancer Market Size, Share & Industry Analysis, By Drug Class (PD-1 Inhibitors, Platinum Compounds, Taxanes, VEGFR/Multikinase Inhibitors, Progestins, and Others), By Cancer Type (Endometrioid Adenocarcinoma, Serous Endometrial Carcinoma, Clear Cell Carcinoma, and Others), By Age Group (Pediatric and Adults), By Therapy (Chemotherapy, Immunotherapy, Targeted Therapy, Hormonal Therapy, and Others), By Route of Administration (Oral and Parenteral), By Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, and Others) and Regional Forecast, 2026-2034

The global endometrial cancer market size was valued at USD 2.66 billion in 2025. The market is projected to grow from USD 3.01 billion in 2026 to USD 7.90 billion by 2034, exhibiting a CAGR of 12.84% during the forecast period.

The global market comprises therapies used for the treatment of early-stage, advanced, recurrent, and metastatic endometrial cancer. The market is gaining momentum as the number of diagnosed cases increases, biomarker testing becomes more common, and treatment decisions shift toward immunotherapy-based and targeted combinations. As healthcare systems focus on improving survival outcomes in gynecologic cancers, companies are strengthening their product portfolios through label expansions, clinical trial readouts, and regulatory approvals.

• For instance, in January 2025, GSK plc received expanded approval from the European Commission for JEMPERLI (dostarlimab) plus Chemotherapy for all adult patients with primary advanced or recurrent endometrial cancer. Such developments support market growth as broader first-line approvals increase access to immunotherapies for a larger endometrial cancer patient population.

Major players, such as Merck & Co., Inc., Eisai Co., Ltd., GSK plc, and AstraZeneca PLC, are streamlining their resources toward research and development, expanding their pipelines, diversifying their offerings, and improving patient outcomes.

ENDOMETRIAL CANCER MARKET TRENDS

Growing Pipeline Activity for Novel Immuno-Oncology and Targeted Agents Is an Emerging Trend Observed

A significant global trend in the market is a shift toward an innovation-led phase. As companies expand development beyond standard Chemotherapy and established checkpoint inhibitors, the trend is gaining momentum as patients with advanced, recurrent, or biomarker-defined disease still need better treatment options after first-line therapy. As a result, pharmaceutical companies are investing in novel immuno-oncology combinations, antibody-drug conjugates, and targeted agents that can improve response rates, extend disease control, and support more personalized treatment pathways. Key companies operating in the market are focusing on pipeline development to address this unmet clinical demand.

• For instance, in June 2025, Daiichi Sankyo dosed its first patient in the global Phase 3 DESTINY-Endometrial01 trial evaluating ENHERTU in combination with rilvegostomig or pembrolizumab as first-line therapy for patients with HER2-expressing primary advanced or recurrent endometrial cancer. The study compared these investigational regimens with the current standard of care, supporting the use of immuno-oncology combinations to address biomarker-defined endometrial cancer populations.

MARKET DYNAMICS

MARKET DRIVERS

Download Free sample to learn more about this report.

Rising Incidence of Endometrial Cancer to Drive Market Growth

A key factor driving the global endometrial cancer market growth is the rising number of diagnosed patients across developed and emerging regions. This elevated rise in patient population is linked to aging populations, obesity, metabolic disorders, and better cancer detection. As the patient base grows, demand for innovative therapy options increases. This also encourages hospitals and cancer centers to strengthen gynecologic oncology services, improve access to molecular testing, and adopt newer treatment protocols. Additionally, higher recurrence rates in advanced disease continue to drive global market demand.

• For instance, in 2022, the World Cancer Research Fund reported 420,368 new cases of endometrial cancer. The rising incidence of endometrial cancer is expected to drive demand for the treatment.

MARKET RESTRAINTS

High Treatment Cost to Hamper Market Growth

The high cost of these advanced regimens remains a key restraint in the market. Treatments such as immune checkpoint inhibitors and targeted therapies often require repeated dosing, biomarker testing, monitoring, and adverse-event management, which increases the total cost of care. As a result, even when these therapies show meaningful survival benefits, their adoption can be slower in cost-sensitive healthcare systems, countries with limited reimbursement, and patient groups facing high out-of-pocket spending. This creates a gap between clinical innovation and real-world access, thereby limiting the market's full growth potential.

• For instance, in January 2026, NIH published an article titled ‘Cost-effectiveness of lenvatinib plus pembrolizumab as the second-line treatment for advanced endometrial carcinoma’ which reported that although clinically beneficial for advanced or recurrent endometrial carcinoma, it was not covered by Taiwan’s National Health Insurance at the time of the study, and imposed a high treatment cost burden.

MARKET OPPORTUNITIES

Expansion of Biomarker-Guided Treatment Approaches to Offer Several Growth Opportunities

The global market is creating strong growth opportunities as treatment decisions increasingly move toward biomarker-based patient selection. Advanced and recurrent endometrial cancer includes different molecular subgroups, since not all patients respond equally to standard Chemotherapy or immunotherapy alone. As a result, companies are developing targeted combinations for HER2-expressing, dMMR/MSI-H, and pMMR patient groups to improve response rates, extend survival, and expand treatment options within more defined patient populations. Such development supports the wider adoption of precision oncology in endometrial cancer care.

• For instance, in October 2025, Merck & Co., Inc. announced that KEYTRUDA (pembrolizumab) plus LENVIMA (lenvatinib) demonstrated a durable 5-year survival benefit versus Chemotherapy in patients with advanced endometrial carcinoma after one prior platinum-based regimen. The combination showed a 5-year overall survival rate of 16.7% in pMMR patients, compared with 7.3% with Chemotherapy, offering better patient outcomes.

MARKET CHALLENGES

Inconsistent Clinical Benefit Across Earlier-Stage Treatment Settings Remains a Key Market Challenge

One of the major challenges faced by the market is the inconsistent clinical benefit of therapies when evaluated in broader or earlier-stage treatment settings. These factors create uncertainty for companies as failed or mixed trial outcomes can delay label expansion, reduce physician confidence in some treatment approaches, and slow investment in similar combinations. As a result, while the market continues to grow, companies must generate stronger evidence across different disease stages and patient subgroups before these therapies can be adopted more widely.

• For instance, in May 2024, Merck & Co., Inc. announced that the Phase 3 KEYNOTE-B21 trial evaluating KEYTRUDA (pembrolizumab) in combination with chemotherapy, with or without radiotherapy, did not meet its primary endpoint of disease-free survival in patients with newly diagnosed high-risk endometrial cancer following surgery with curative intent. Such developments highlight how immunotherapy-based combinations that perform well in advanced settings may still face clinical setbacks in earlier-stage or adjuvant treatment populations, creating challenges for broader market expansion.

Segmentation Analysis

By Drug Class

PD-1 Inhibitors Segment Dominated due to their Higher Treatment Value Compared With Conventional Generic Chemotherapy

Based on drug class, the market is categorized into PD-1 inhibitors, platinum compounds, taxanes, VEGFR/multikinase inhibitors, progestins, PD-L1 inhibitors, and others.

PD-1 inhibitors dominated the market as it plays a central role in the treatment of advanced and recurrent endometrial cancer, especially through the use of pembrolizumab and dostarlimab used in combination with Chemotherapy and as maintenance therapy. Additionally, their dominance is supported by broader approvals across mismatch repair subgroups, stronger survival evidence, and higher treatment value compared with conventional generic Chemotherapy.  

• For instance, in July 2023, HUTCHMED Limited received Breakthrough Therapy Designation from China’s National Medical Products Administration for the combination of fruquintinib and sintilimab (a PD-1 antibody) for the treatment of patients with advanced endometrial cancer (“EMC”) with pMMR1 tumors that have failed at least one line of platinum-based therapy.

The PD-L1 inhibitors segment is expected to grow at a CAGR of 19.39% over the forecast period.

To know how our report can help streamline your business, Speak to Analyst

By Cancer Type

Large Patient Pool of Endometrioid Adenocarcinoma Propelled the Growth in the Segment

Based on cancer type, the market is segmented into endometrioid adenocarcinoma, serous endometrial carcinoma, clear cell carcinoma, carcinosarcoma, and others.

In 2025, the endometrioid adenocarcinoma accounted for the largest share as it is the most common histological subtype of endometrial carcinoma and represents the largest diagnosed patient pool. Since this subtype accounts for the majority of cases, it generates higher treatment volume across surgery, Chemotherapy, hormonal therapy, immunotherapy, and recurrence management. This large patient pool creates a larger commercial base for drug utilization, leading to the Segment's dominance. Key companies are focusing on research and development, followed by subsequent approvals from regulatory bodies, further supporting the segment's growth.

• For instance, in August 2025, Genmab A/S received Breakthrough Therapy Designation (BTD) from the U.S. FDA for rinatabart sesutecan (Rina-S), an investigational folate receptor alpha (FRα)-directed, for the treatment of adult patients with recurrent or progressive endometrial cancer (EC) whose disease has progressed on or after prior treatment with a platinum-containing regimen and a PD-(L)1 therapy.

The others segment is projected to grow at a CAGR of 15.03% during the forecast period.

By Age Group

Higher Systemic Therapy Use Boosted Adult Segment Growth

Based on age group, the market is segmented into pediatric and adults.

In 2025, the adults segment is likely to dominate the market as endometrial cancer mainly affects post-menopausal women, while pediatric cases are extremely rare. The adult segment has a much larger diagnosed population, higher systemic therapy use, and a greater need for long-term oncology management. As a result, most product approvals, clinical trials, reimbursement decisions, and treatment guidelines are focused on adult patients, which keeps this segment dominant throughout the forecast period.

• For instance, in January 2026, the American Cancer Society stated that endometrial cancer mainly affects post-menopausal women, the average age at diagnosis is 60, and the disease is uncommon in women under 45. This supports the dominance of the segment, as the core treated population is concentrated among older adult women.

The pediatric segment is projected to grow at a CAGR of 16.79% during the forecast period.

By Therapy

Use of Chemotherapy as A Standard Endometrial Cancer Treatment to Lead the Dominance of the Segment

Based on therapy, the market is segmented into chemotherapy, immunotherapy, targeted therapy, hormonal therapy, and others.

In 2025, chemotherapy dominated the market as platinum-taxane regimens remain widely used as the treatment backbone for advanced, recurrent, and high-risk endometrial cancer. Even when immunotherapy is added, carboplatin and paclitaxel continue to be used in many approved first-line regimens, which keeps chemotherapy volumes high. The segment’s high share is further supported by broad availability, physician familiarity, generic competition, regulatory approval, and use across multiple patient groups regardless of biomarker status.

• For instance, in June 2024, Merck & Co., Inc. announced that the U.S. FDA approved KEYTRUDA with carboplatin and paclitaxel, followed by KEYTRUDA alone, for adult patients with primary advanced or recurrent endometrial carcinoma regardless of mismatch repair status. This supports chemotherapy dominance as even major immunotherapy approvals continue to rely on chemotherapy as the starting treatment backbone.

The immunotherapy segment is projected to grow at a CAGR of 18.69% during the forecast period.

By Route of Administration

Shift Toward Immunotherapy Plus Chemotherapy Supported Parenteral Segment Growth

Based on route of administration, the market is segmented into oral and parenteral.

In 2025, the parenteral segment held the largest endometrial cancer market share. Many core therapies for endometrial cancer are given by intravenous infusion. This route is preferred for hospital-based oncology treatment as it enables controlled dosing, infusion monitoring, and management of adverse events during systemic therapy. As a result, the shift toward immunotherapy plus chemotherapy further strengthens the parenteral segment. New product launches in the segment align with the trend.

• For instance, in July 2024, AstraZeneca announced that IMFINZI plus Chemotherapy was approved in the U.S. for adult patients with primary advanced or recurrent dMMR endometrial cancer, with treatment involving chemotherapy followed by IMFINZI monotherapy.

The oral segment is projected to grow at a CAGR of 13.83% during the forecast period.

By Distribution Channel

Strategic Collaboration with Hospitals to Expand Access to Lead Hospital Pharmacies Segment Growth

Based on distribution channel, the market is segmented into hospital pharmacies, drug stores & retail pharmacies, online pharmacies, and specialty pharmacies.

The hospital pharmacies segment is poised to dominate the market as endometrial cancer treatment is highly specialist-driven and often involves infusion-based therapies, oncology supervision, biomarker review, and toxicity monitoring. Advanced and recurrent cases usually require treatment in hospitals or cancer centers where chemotherapy and immunotherapy products can be prepared, administered, and monitored safely. As a result, hospital pharmacies capture a larger share of high-value injectable oncology medicines. Underscoring this importance, key market players focus on strategic collaborations to expand access.

• For instance, in December 2025, GSK plc collaborated with the pan-Canadian Pharmaceutical Alliance (pCPA) for Jemperli (dostarlimab for injection) in combination with carboplatin and paclitaxel for the treatment of adult patients with primary advanced or first recurrent endometrial cancer who are candidates for systemic therapy, including patients with mismatch repair proficient (MMRp)/microsatellite stable (MSS) tumors.

The online pharmacies segment is projected to grow at a CAGR of 16.92% over the study period.

Endometrial Cancer Market Regional Outlook

By geography, the market is categorized into Europe, North America, Asia Pacific, Latin America, and the Middle East & Africa.

North America

To get more information on the regional analysis of this market, Download Free sample

North America held the dominant share in 2024 at USD 1.11 billion and maintained its leading position in 2025 at USD 1.24 billion. The market is growing in the region due to high disease diagnosis, strong oncology infrastructure, and faster adoption of immunotherapy-based combinations. Broad access to biomarker testing and favorable reimbursement support the use of premium therapies.

U.S. Endometrial Cancer Market

Given North America's substantial contribution and the U.S. dominance in the region, the U.S. market is poised to reach around USD 1.29 billion by 2026, accounting for roughly 43.00% of the global sales.

Europe

Europe is projected to grow at 12.49% over the coming years, the second-highest among all regions. The market is expected to reach a valuation of USD 0.83 billion by 2026. Growth across the region is supported by expanding regulatory approvals, national cancer programs, and wider use of guideline-based treatment. Increasing access to PD-1 inhibitors and chemotherapy-immunotherapy combinations is improving treatment adoption.

U.K. Endometrial Cancer Market

The U.K. market is poised to reach around USD 0.14 billion in 2026, representing roughly 4.51% of the global sales.

Germany Endometrial Cancer Market

Germany's market is projected to reach approximately USD 0.16 billion by 2026, equivalent to around 5.36% of the global sales.

Asia Pacific

Asia Pacific is estimated to reach USD 0.53 billion by 2026, securing the position of the third-largest region in the market. The market is growing in the region due to a large patient pool, rising cancer awareness, and improving access to oncology care.

Japan Endometrial Cancer Market

The Japanese market is poised to reach around USD 0.13 billion by 2026, accounting for approximately 4.19% of the global sales.

China Endometrial Cancer Market

China's market is projected to be among the largest worldwide, with 2026 revenue estimates around USD 0.22 billion, accounting for approximately 7.32% of global sales.

India Endometrial Cancer Market

The Indian market is expected to reach around USD 0.05 billion by 2026, accounting for roughly 1.58% of global revenues.

Latin America and the Middle East & Africa

The Latin America and Middle East & Africa regions are expected to witness moderate growth in the market during the forecast period. The market in Latin America is estimated to reach a valuation of USD 0.15 billion by 2026. Growth in Latin America is supported by improved cancer screening, greater specialist access, and the gradual adoption of advanced oncology medicines. Public and private healthcare systems are expanding access to cancer treatment in major markets such as Brazil and Mexico. This creates opportunities for broader use of endometrial cancer therapies. In the Middle East & Africa, the GCC is set to reach USD 0.04 billion by 2026.

South Africa Endometrial Cancer Market

The South African market is projected to reach approximately USD 0.02 billion by 2026, accounting for roughly 0.56% of global revenues.

COMPETITIVE LANDSCAPE

Key Industry Players

Key Players Focus on Biomarker-Based Treatment Development to Strengthen their Market Progress

The global market is moderately consolidated, with companies such as Merck & Co., Inc., GSK plc, Eisai Co., Ltd., AstraZeneca PLC, Daiichi Sankyo Company, Limited, Pfizer Inc., Fresenius Kabi AG, Hikma Pharmaceuticals PLC, Teva Pharmaceutical Industries Ltd., and Accord Healthcare Limited accounting for a significant share. Ongoing product approvals, label expansions, clinical trial advancements, and biomarker-based treatment development are further helping these companies strengthen their market positions and improve their revenue share in the sector.

• For instance, in December 2025, Daiichi Sankyo Co., Ltd. initiated the DESTINYEndometrial02 phase 3 trial evaluating ENHERTU (trastuzumab deruxtecan) with or without radiotherapy, compared with standard-of-care Chemotherapy with or without radiotherapy as adjuvant treatment (after surgery) in patients with HER2-expressing (IHC 3+/2+) endometrial cancer.

Other notable participants in the global market include Sandoz Group AG, Viatris Inc., Bristol Myers Squibb Company, Cipla Limited, Karyopharm Therapeutics Inc., and Acrivon Therapeutics, Inc. These companies are expected to focus on generic oncology supply, biomarker-led clinical trials, and hospital-based oncology distribution to strengthen their market positions. The rest of the market remains fragmented among regional manufacturers, specialty oncology companies, and injectable generic suppliers serving high-volume chemotherapy and supportive cancer treatment segments.

LIST OF KEY ENDOMETRIAL CANCER COMPANIES PROFILED

• Merck & Co., Inc. (U.S.)
• Eisai Co., Ltd.(Japan)
• GSK plc (U.K.)
• AstraZeneca PLC (U.K.)
• Pfizer Inc. (U.S.)
• Fresenius Kabi AG (Germany)
• Hikma Pharmaceuticals PLC (U.K.)
• Teva Pharmaceutical Industries Ltd. (Israel)
• Accord Healthcare Limited (U.K.)
• Bristol Myers Squibb Company (U.S.)

KEY INDUSTRY DEVELOPMENTS

• April 2026: BioNTech SE announced positive results from the primary analysis of a Phase 2 cohort evaluating trastuzumab pamirtecan (BNT323/DB-1303) in patients with HER2-expressing advanced endometrial cancer whose disease progressed on or after first-line chemotherapy, with or without prior checkpoint inhibitor treatment.
• April 2026: Utepreva LLC launched the Utepreva Endometrial Sampler, a patented, FDA 510(k)-cleared, single-use endometrial sampling device engineered to enhance tissue capture and support early diagnostic evaluation of endometrial cancer.
• December 2024: IDEAYA Biosciences, Inc. dosed the first patient in the Phase 1 trial evaluating the combination of IDE161, the investigational, potential first-in-class, small molecule poly (ADP-ribose) glycohydrolase, or PARG, inhibitor, in combination with Merck's anti-PD-1 therapy, KEYTRUDA (pembrolizumab), in patients with high microsatellite instability (MSI-high) and microsatellite stable (MSS) disease.
• December 2024: Repare Therapeutics Inc. reported positive data from its MYTHIC Phase 1 gynecologic expansion trial evaluating lunresertib with camonsertib (Lunre+Camo) at the recommended Phase 2 dose (RP2D) in patients with endometrial cancer and platinum-resistant ovarian cancer (PROC) harboring lunresertib-sensitizing biomarkers.
• August 2024: GSK plc received approval from the U.S. FDA for Jemperli (dostarlimab) in combination with carboplatin and paclitaxel, followed by Jemperli as a single agent, for the treatment of adult patients with primary advanced or recurrent endometrial cancer.

REPORT COVERAGE

The report provides a comprehensive global endometrial cancer market analysis. It covers detailed market analysis across drug class, cancer type, age group, therapy, route of administration, and distribution channel. It examines the demand for therapies used in endometrioid adenocarcinoma, serous endometrial carcinoma, clear cell carcinoma, carcinosarcoma, and other endometrial cancer types, while also assessing the role of PD-1 inhibitors, platinum compounds, taxanes, VEGFR/multikinase inhibitors, progestins, PD-L1 inhibitors, and other drug classes in current treatment practice. The study further provides regional insights across key geographies, competitive landscape analysis, company profiling, recent developments, and evaluation of the major factors driving, restraining, and shaping future opportunities in the market.

Request for Customization   to gain extensive market insights.

Report Scope & Segmentation